Elaine and Sydney Sussman Cardiac Catheterization Laboratory, University of Miami Hospital, Miller School of Medicine, Miami, Florida.
Catheter Cardiovasc Interv. 2013 Oct 1;82(4):E587-91. doi: 10.1002/ccd.24678. Epub 2013 Mar 25.
In the era of transcatheter aortic valve therapies, the presence of residual paravalvular regurgitation (PVR) after transcatheter aortic valve replacement (TAVR) may become a clinical challenge. Management of late symptomatic PVR is still unknown. We describe a challenging case of percutaneous closure attempt of a clinically significant PVR in a patient after Edwards SAPIEN (Edwards Lifesciences, CA) TAVR.
在经导管主动脉瓣治疗时代，经导管主动脉瓣置换（TAVR）后残余瓣周漏（PVR）的存在可能成为临床挑战。对于晚期有症状的 PVR 的处理目前仍不清楚。我们描述了一例经导管封堵术尝试治疗一例 Edwards SAPIEN（爱德华生命科学公司，加利福尼亚州）TAVR 后有临床意义的 PVR 的挑战性病例。
